Fintel · Aug 20, 2026
NYSE · RMD
ResMed Inc.
Healthcare · Medical - Instruments & Supplies
$240.33
Up+$4.57 (+1.94%)
Updated Aug 31, 2026, 9:37 AM
SID Score
6.8/10
Composite research score
Smart Money
55/100
Neutral
- Market cap
- 36.98B
- P/E ratio
- 25.71
- Dividend yield
- 0.94%
- 52-week range
- $180.27 – $277.67
- Volume
- 1.39M
- Avg. volume
- 1.04M
Price performance
RMD price history
1M range · 20 trading sessions · Daily adjusted prices
RMD closed at $240.33 after 20 trading sessions, up 11.68% for the selected period.
- Last close
- $240.33
- Period change
- +11.68%
- Period low
- $211.94
- Period high
- $240.33
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 28, 2026 | $236.64 | $241.06 | $235.01 | $240.33 | 1.39M |
| Aug 27, 2026 | $233.06 | $237.94 | $232.29 | $235.76 | 1.59M |
| Aug 26, 2026 | $233.66 | $237.76 | $232.10 | $235.69 | 1.54M |
| Aug 25, 2026 | $232.22 | $238.37 | $231.885 | $236.59 | 1.76M |
| Aug 24, 2026 | $231.00 | $233.23 | $228.87 | $232.45 | 1.11M |
| Aug 21, 2026 | $229.44 | $234.14 | $228.5386 | $231.52 | 1.73M |
| Aug 20, 2026 | $229.03 | $232.99 | $228.38 | $228.44 | 1.29M |
| Aug 19, 2026 | $221.00 | $231.04 | $220.44 | $230.65 | 1.21M |
| Aug 18, 2026 | $221.00 | $223.47 | $219.97 | $219.98 | 1.3M |
| Aug 17, 2026 | $222.68 | $223.94 | $218.655 | $220.37 | 1.45M |
| Aug 14, 2026 | $228.12 | $228.5475 | $223.79 | $224.46 | 1.19M |
| Aug 13, 2026 | $226.00 | $227.76 | $223.22 | $226.74 | 1.17M |
| Aug 12, 2026 | $218.73 | $226.64 | $218.73 | $226.00 | 1.4M |
| Aug 11, 2026 | $218.78 | $225.76 | $215.71 | $224.84 | 1.24M |
| Aug 10, 2026 | $211.89 | $220.405 | $210.58 | $220.05 | 1.72M |
| Aug 7, 2026 | $207.18 | $215.50 | $202.00 | $211.94 | 3.81M |
| Aug 6, 2026 | $224.84 | $226.12 | $222.20 | $223.24 | 1.79M |
| Aug 5, 2026 | $222.00 | $225.00 | $220.49 | $224.03 | 1.75M |
| Aug 4, 2026 | $212.26 | $223.21 | $210.93 | $223.14 | 1.74M |
| Aug 3, 2026 | $214.00 | $217.5692 | $212.86 | $215.19 | 1.47M |
Latest RMD news
The latest Smart Investors Daily articles mentioning RMD.
Stock researchCompany · Overview
RMD research
Overview
Company profile and research snapshot.
Company profile
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $296.00
- Implied upside
- —
- Analysts
- 25
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 19, 2026 | Rothschild & Co | Neutral | — |
| Aug 7, 2026 | Wells Fargo | Equal-Weight | — |
| Aug 7, 2026 | Keybanc | Overweight | — |
| Aug 7, 2026 | RBC Capital | Sector Perform | — |
| Aug 7, 2026 | Piper Sandler | Neutral | — |
News briefing
No generated briefing is available yet.
Yahoo · Aug 19, 2026
Moderna upgraded, Baidu downgraded: Wall Street's top analyst calls
Moderna upgraded, Baidu downgraded: Wall Street's top analyst calls
Benzinga · Aug 19, 2026
Rothschild & Co Initiates Coverage On ResMed with Neutral Rating, Announces Price Target of $230
Rothschild & Co analyst Jackson Philips initiates coverage on ResMed (NYSE:RMD) with a Neutral rating and announces Price Target of $230.
Yahoo · Aug 17, 2026
Resmed Announces Appointment of Carol Burt as Lead Director and Planned Retirement of Director Ron Taylor
Nominating and Governance Chair Carol Burt to become Lead Director.Ron Taylor to retire after more than 21 years of service on Resmed’s Board of Directors. SAN DIEGO, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced that Carol Burt will become Lead Director on November 15, 2026. She will succeed Ron Taylor, Resmed’s current Lead Director, who is not standing for reelec
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
